Vitra Bioscience Closes Doors as Investors Pull Out; Company Selling Cell-Assay Tech | GenomeWeb

Vitra Bioscience, which commercially launched its flagship CellCard multiplexed cell-based assay system at the beginning of this year, has closed its doors and is currently seeking potential suitors to acquire all of the company's assets, according to two former Vitra officials.

Ilya Ravkin, the company's co-founder and chief technology officer, told CBA News at IBC's High-Content Analysis conference held earlier this month in Washington, DC, that Vitra has "shut down" operations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.